Compile Data Set for Download or QSAR
Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 743
TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38015(US10093635, Example 54 | 2-(2-fluoro-6-((4-(((1,1,...)
Affinity DataIC50: 550nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38014(US10093635, Example 53 | 1,1,1,3,3,3-hexafluoropro...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38016(US10093635, Example 55 | 1,1,1,3,3,3-hexafluoropro...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38018(US10093635, Example 56 | 4-(2-chloro-6-((4- (((1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37951(US10093635, Example 1 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37954(US10093635, Example 2 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37955(US10093635, Example 3 | 4-(2-((4-(((1,1,1,3,3,3-He...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37956(US10093635, Example 4 | 4-(5-Chloro-2-((4-(((1,1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37967(US10093635, Example 13 | 2-(5-Chloro-2-((4-(((1,1,...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37970(US10093635, Example 14 | 2-(2-((4-(((1,1,1,3,3,3-H...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37972(US10093635, Example 15 | 5-(2-((4-(((1,1,1,3,3,3-H...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37973(US10093635, Example 16 | 1-(2-((4-(((1,1,1,3,3,3-H...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37974(US10093635, Example 17 | 2-(3-((4-(((1,1,1,3,3,3-h...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37975(US10093635, Example 18 | 4-(2-((4-(((1,1,1,3,3,3-h...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37976(US10093635, Example 19 | 1-(3-((4-(((1,1,1,3,3,3-h...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37978(US10093635, Example 20 | 1,1,1,3,3,3-hexafluoropro...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37957(US10093635, Example 5 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37960(US10093635, Example 6 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37961(US10093635, Example 7 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37962(US10093635, Example 8 | 1,1,1,3,3,3-Hexafluoroprop...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37963(US10093635, Example 9 | 2-(2-((2-((4-(((1,1,1,3,3,...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37964(US10093635, Example 10 | 2-(2-((4-Chloro-2-((4-(((...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37965(US10093635, Example 11 | 2-(2-((2-Fluoro-6-((4-(((...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37966(US10093635, Example 12 | N-(2-((5-Chloro-2-((4-(((...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37987(US10093635, Example 29 | 1-((2-fluoro-6-((4-(((1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37988(US10093635, Example 30 | 1-((2-((4-(((1,1,1,3,3,3-...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37990(US10093635, Example 31 | 1,1,1,3,3,3-hexafluoropro...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37991(US10093635, Example 32 | 1-((2-fluoro-6-((4-(((1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37992(US10093635, Example 33 | 1-((2,3-difluoro-6-((4-((...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37993(US10093635, Example 34 | 1-((4,5-difluoro-2-((4-((...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37994(US10093635, Example 35 | 1-((5-cyano-2-((4-(((1,1,...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37995(US10093635, Example 36 | 1-((2-cyano-6-((4-(((1,1,...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37979(US10093635, Example 21 | 1,1,1,3,3,3-hexafluoropro...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37980(US10093635, Example 22 | 1-(2-((4-(((1,1,1,3,3,3-H...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37981(US10093635, Example 23 | 1-((2-Chloro-6-((4-(((1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37982(US10093635, Example 24 | 4-(2-Fluoro-6-((4-(((1,1,...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37983(US10093635, Example 25 | 4-(2-Fluoro-6-((4-(((1,1,...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37984(US10093635, Example 26 | 1-((2-Cyano-4-fluoro-6-((...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37985(US10093635, Example 27 | 1-((2-((4-(((1,1,1,3,3,3-...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37986(US10093635, Example 28 | 1-((3-((4-(((1,1,1,3,3,3-...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38005(US10093635, Example 45 | (1S,3R)-3-(2-((4-(((1,1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38006(US10093635, Example 46 | (1R,3R)-3-(2-((4-(((1,1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38007(US10093635, Example 47 | (1r,3r)-3-(2-((4-(((1,1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38009(US10093635, Example 48 | 4-(3-((4-(((1,1,1,3,3,3-h...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38010(US10093635, Example 49 | 2-(2-chloro-6-((4-(((1,1,...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38011(US10093635, Example 50 | 1,1,1,3,3,3-hexafluoropro...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38012(US10093635, Example 51 | 1,1,1,3,3,3-hexafluoropro...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM38013(US10093635, Example 52 | 1,1,1,3,3,3-hexafluoropro...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37996(US10093635, Example 37 | 1-((2,3-difluoro-6-((4-((...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM37997(US10093635, Example 38 | 1-((3-fluoro-6-((4-(((1,1...)
Affinity DataIC50: 5.50E+3nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent

Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: